# Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®

> **NCT00269477** · PHASE2 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 145 (actual)

## Conditions studied

- Meningitis
- Meningococcal Infection

## Interventions

- **BIOLOGICAL:** Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
- **BIOLOGICAL:** Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
- **BIOLOGICAL:** Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
- **BIOLOGICAL:** Meningococcal Polysaccharide Diphtheria Toxoid Conjugate

## Key facts

- **NCT ID:** NCT00269477
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2007-02
- **Final completion:** 2007-12
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2016-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00269477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00269477, "Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT00269477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*